Teilnahme an Studien

Forschung ist ein fester Bestandteil unseres medizinischen 
Selbstverständnisses. In mehreren Fachkliniken unseres Hauses beteiligen wir uns aktiv an wissenschaftlichen Studien, um moderne Diagnostik- und Therapieverfahren weiterzuentwickeln und unseren Patientinnen und Patienten Zugang zu innovativen Behandlungsoptionen zu ermöglichen.

BNT113-01
An open label Phase II randomized trial of BNT 113 in combination with pembrolizumab versus monotherapy as a first line therapie in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma(HNSCC) which is positive for human papilloma virus 16(HPV 16+) and expressive PD-L1

GSK 221530- Jade
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Registerstudie
„Häufigkeit von HPV-assoziierten Oropharynxtumoren“ (HPV-Registerstudie; Leiter der Studie: Prof. Dr. med. Dirk Beutner, Universitäts-HNO-Klinik Göttingen)

BCP Study (GBG 29)
Breast cancer in Pregnancy

CAPTOR-BC
Comprehensive Analysis Of Spatial, Temporial And Molecular Patterns Of Ribociclib Efficacy And Resistance In Advanced Breast Cancer Patients
Registerstudie Mammakarzinom des Mannes

HerediCaRe-Studie
eine Registerstudie, in Zusammenarbeit mit dem Zentrum für Familiären Brust- und Eierstockkrebs (FBREK)

Tropium-Lung10, D7632C00001
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alteration

eVOLVE-Lung02-D789AC00001
A Phase III, Two –Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to determine the Efficacy of Volrustomig(MEDI5752) versus Pembrolizumab in Combination with Chemotherapy for First-Line-Treatment of Patients with Metastatic Non-Small Cell Lung Cancer(mNSCLC) (eVOLVE-Lung02)

Prism-1
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

GS-US-600-6165, evoke-SCLC-04
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)